CD28 and experimental autoimmune encephalomyelitis: In pre-clinical trials the use of agonistic anti-CD28 (TGN1412) to expand Tregs was highly successful in the treatment of experimental autoimmune encephalomyelitis and adjuvant arthritis in rodent models57, 58, 59, 60.